| Study period |
---|
| Enrolment | Allocation | Post-allocation | Close-out |
---|
| Entrya
| 0 | Day 1–3 | Day 4 | Day 5–8 | Day 10 | Discharge* | Day 30* |
---|
Time point |
Eligibility screen | + | | | | | | | |
Informed consent | + | | | | | | | |
Allocation | | + | | | | | | |
Interventions |
SVPE | | | + | + | + | | | |
Non-SVPE | | | + | + | + | | | |
Assessments |
SVPE procedureb
| | | + | + | + | | | |
Hemodynamicc
| + | + | + | + | + | + | + | |
Biochemistryd
| + | ±‡ | ±‡ | + | ±‡ | + | | |
Infection screeninge
| + | ±‡ | ±‡ | + | ±‡ | + | | + |
Neurologicalf
| + | + | | + | | + | + | + |
- *For patients treated with SVPE. ‡ Assessed as per indication
-
aWithin 14 days of onset of muscle weakness
-
bNumber and duration of each SVPE session and volume of the plasma removed and the replacement fluid infused
-
cBlood pressure, heart rate, body temperature, and pulse oximetry
-
dHemoglobin (g/L), coagulation profile, serum level of calcium, magnesium, albumin, renal, and liver function test
-
eComplete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein, and microbiological investigations to assess CLABSI, CAUTI, and VAP
-
fGBS disability score and MRC sum score